Thus, we have provided proof-of-concept evidence that modulation of intestinal mucus barrier by targeting intestinal PXR or B3galt5 is an attractive strategy for the prevention and therapy of obesity and related metabolic disorders. The gene discussed is NR1I2; the disease is metabolic disease.